Modest growth forecast for global migraine market to 2023

The global migraine treatment market value is expected to undergo a modest increase over the coming years, climbing from $2.5 billion in 2012 to $3.7 billion by 2023, at a compound annual growth rate (CAGR) of 3.6%.

According to a new report from research and consulting firm GlobalData, out of the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK and Japan), the US dominated the migraine space in 2012 with a global share of 77%. It will maintain its market-leading position by 2023, with a higher share of 84%.

GlobalData attributes the anticipated market expansion to the introduction of novel acute migraine therapy classes, which will address the underserved population. Among the drugs that will be launched during the forecast period are Teva and NuPathe’s Zecuity (sumatriptan iontophoretic transdermal system), Allergan’s Levadex (dihydroergotamine), OptiNose’s AVP-825 and SUDA’s SUD-001.